| ||Format||Pages||Price|| |
|PDF Version||6||$42.00||  ADD TO CART|
|Print Version||6||$42.00||  ADD TO CART|
1.1 The purpose of this guide is to establish a framework and context for process understanding for pharmaceutical manufacturing using quality by design (QbD) (Juran, 1992; FDA/ICH Q8). The framework is applicable to both active pharmaceutical ingredient (API) and to drug product (DP) manufacturing. High (detailed) level process understanding can be used to facilitate production of product which consistently meets required specifications. It can also play a key role in continuous process improvement efforts.
1.2 Process Analytical Technology (PAT) is one element that can be used for achieving control over those inputs determined to be critical to a process. It is important for the reader to recognize that PAT is defined as:
2. Referenced Documents (purchase separately) The documents listed below are referenced within the subject standard but are not provided as part of the standard.
E456 Terminology Relating to Quality and Statistics
E2281 Practice for Process and Measurement Capability Indices
E2474 Practice for Pharmaceutical Process Design Utilizing Process Analytical Technology
E2617 Practice for Validation of Empirically Derived Multivariate Calibrations
U.S. Government PublicationsU.S.FDAPAT Guidance Document, Guidance for Industry PATA Framework for Innovative Pharmaceutical Manufacturing and Quality Assurance
ICS Number Code 11.120.01 (Pharmaceutics in general)
UNSPSC Code 85121902(Commercial pharmaceutical services)